Twist Bioscience (TWST) Common Equity (2017 - 2026)

Twist Bioscience has disclosed Common Equity across 10 years of filings, most recently posting $455.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 3.41% year-over-year to $455.1 million; the TTM figure through Mar 2026 stood at $455.1 million (up 3.41% YoY), while the FY2025 annual figure was $473.0 million, changed 0.06% from the prior year.
• Common Equity steadied at $455.1 million in Q1 2026, from $456.1 million in the prior quarter.
• Over the last five years, Common Equity for TWST reached as high as $863.4 million in Q1 2022 and fell as low as $440.1 million in Q1 2025.
• The 5-year median for Common Equity is $560.1 million (2024), against an average of $592.8 million.
• Annual changes were most pronounced in 2022 — Common Equity soared 40.57% — and 2024, when it slipped 25.31%.
• A 5-year view of Common Equity shows it stood at $746.3 million in 2022, then fell by 20.94% to $590.0 million in 2023, then declined by 22.73% to $455.9 million in 2024, then advanced by 0.03% to $456.1 million in 2025, then slipped by 0.22% to $455.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $455.1 million, $456.1 million, and $473.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.